Loading...
Market
How will major pharmaceutical companies respond to myocarditis study by end of 2024?
2
Resolution / Starting Odds
Acknowledge and propose further studies • 25%
Deny correlation and defend vaccine safety • 25%
Announce new vaccine formulations • 25%
No official response • 25%
Press releases or official statements from major pharmaceutical companies
Story
Study of 1.7 Million Children Links COVID mRNA Vaccines to 37 Cases of Myocarditis and Pericarditis in Vaccinated Kids
Oct 9, 2024, 06:42 AM
A recent study involving 1.7 million children has revealed a significant correlation between COVID-19 mRNA vaccinations and the occurrence of heart-related issues, specifically myocarditis and pericarditis. The findings indicate that all reported cases of these conditions were among vaccinated children, with no instances recorded in unvaccinated children. The study highlights that 37 cases of heart damage were identified per million vaccinated children, raising concerns about the safety of mRNA vaccines for younger populations. Medical professionals and commentators have expressed alarm over these results, questioning the implications for public health policy regarding vaccinations in children.
View original story
Similar markets
Update vaccination guidelines • 25%
Initiate new studies • 25%
Issue a public warning • 25%
No significant action • 25%
Implement moratorium • 25%
Conduct further research • 25%
Ignore findings • 25%
Issue public warnings • 25%
Increased monitoring • 25%
Policy revision • 25%
Public reassurance • 25%
No action taken • 25%
Increase in vaccination age limits • 25%
Introduction of additional health screenings • 25%
No change in current policies • 25%
Other policy changes • 25%
No response • 25%
Denial of contamination claims • 25%
Acknowledgement of contamination and corrective measures • 25%
Legal action against claimants • 25%
Recall of early batches • 25%
Modification of production process • 25%
Increased monitoring/reporting • 25%
No significant action taken • 25%
Increased vaccine hesitancy • 25%
No significant change • 25%
Increased trust in vaccines • 25%
Public divided • 25%
Pfizer • 25%
Moderna • 25%
Both • 25%
Neither • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Increase by 5% or more • 25%
No significant change • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%